{"id":16859,"date":"2024-03-11T22:48:35","date_gmt":"2024-03-12T02:48:35","guid":{"rendered":"https:\/\/sosv.com\/?p=16859"},"modified":"2024-03-12T16:01:17","modified_gmt":"2024-03-12T20:01:17","slug":"announcing-the-2024-human-health-100","status":"publish","type":"post","link":"https:\/\/sosv.com\/announcing-the-2024-human-health-100\/","title":{"rendered":"Announcing the 2024 Human Health 100"},"content":{"rendered":"\n
\"Human<\/figure>\n\n\n\n

Welcome to the third annual SOSV Human Health 100. The list features SOSV\u2019s 100 most exciting companies in the health category, which for SOSV ranges very widely, from assistive robotics and remote care to therapeutics and diagnostics. <\/p>\n\n\n\n

In the past two years (see the 2023<\/a> and 2022<\/a> lists), venture rounds and company valuations grew strongly, but in the past year funding has become much harder to secure and valuations are fragile at best. We asked founders in our recently concluded and very well attended VC-Founder Health Matchup<\/a> (more on that below) what they thought of the funding environment: 71% reported that it was worse than prior years; no respondent reported it was better. <\/p>\n\n\n\n

We see that trend in our Health 100. As in past years, about 2\/3 of the companies are at the seed stage, 1\/3 at Series A or more, and 2 have reached \u2018Late stage\u2019 (unicorns Opentrons and Formlabs). Compared to the strong numbers the Health 100 posted in the past two years, growth was modest. The Health 100\u2019s aggregate valuation is $6.67 billion<\/strong> (+3% from $5.47B in 2023), and all told the Health 100 have raised $1.43 billion<\/strong> (+1% from $1.42B in 2023).<\/p>\n\n\n\n

SOSV, which invests starting at pre-seed and continues through later stages, has invested $99 million<\/strong> (+3% from $96M in 2023) in the 100. Due to the slowdown in follow-on investing last year, SOSV\u2019s investments were mostly in new companies entering our programs or raising seed rounds.<\/p>\n\n\n\n

Progress of the Health 100 – 2022-2024<\/h2>\n\n\n\n
<\/td>Total Valuation<\/mark><\/strong><\/td>Total Raised<\/mark><\/strong><\/td>SOSV Funding<\/mark><\/strong><\/td>Countries<\/mark><\/strong><\/td>Female Founders<\/mark><\/strong><\/td>PhD Founders<\/mark><\/strong><\/td><\/tr>
2022<\/mark><\/strong><\/td>$5.65B<\/td>$1.0B<\/td>$73M<\/td>19<\/td>30%<\/td>62%<\/td><\/tr>
2023<\/mark><\/strong><\/td>$6.47B<\/td>$1.42B<\/td>$96M<\/td>17<\/td>30%<\/td>67%<\/td><\/tr>
2024<\/mark><\/strong><\/td>$6.67B<\/td>$1.43B<\/td>$99M<\/td>16<\/td>35%<\/td>70%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Note: this table is based on actual funding amounts.<\/p>\n\n\n\n

This year\u2019s list welcomes 16 newcomers<\/strong>, who are listed below. Individual companies on the Health 100 experience ups and downs due to new fundings, regulatory breakthroughs and commercial partnerships. Joining or leaving this list is not a reliable indicator of future outcomes!<\/p>\n\n\n\n

The Health 100 Founders<\/h2>\n\n\n\n

As with the SOSV Climate Tech 100, the diversity and sophistication of our health companies and founders is striking.<\/p>\n\n\n\n

\n
\n